Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides

The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs. Moreover, it might be addressed in prodrug strategies of poorly absorbed drugs....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bajraktari-Sylejmani, Gzona (VerfasserIn) , Linde, Teresa von (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Haefeli, Walter E. (VerfasserIn) , Sauter, Max (VerfasserIn) , Weiß, Johanna (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 1 August 2022
In: Pharmaceutics
Year: 2022, Jahrgang: 14, Heft: 8, Pages: 1-11
ISSN:1999-4923
DOI:10.3390/pharmaceutics14081610
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics14081610
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/14/8/1610
Volltext
Verfasserangaben:Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss

MARC

LEADER 00000caa a2200000 c 4500
001 1816491004
003 DE-627
005 20230426125658.0
007 cr uuu---uuuuu
008 220913s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/pharmaceutics14081610  |2 doi 
035 |a (DE-627)1816491004 
035 |a (DE-599)KXP1816491004 
035 |a (OCoLC)1361696609 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bajraktari-Sylejmani, Gzona  |e VerfasserIn  |0 (DE-588)1152395823  |0 (DE-627)1013994760  |0 (DE-576)499867106  |4 aut 
245 1 0 |a Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides  |c Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss 
246 3 0 |a one fifteen 
264 1 |c 1 August 2022 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 13.09.2022 
520 |a The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs. Moreover, it might be addressed in prodrug strategies of poorly absorbed drugs. We hypothesised that the cyclic drug peptides octreotide and pasireotide could be substrates of this transporter because their diameter can resemble the size of dipeptides or tripeptides due to their strong structural curvature and because they reach the systemic circulation in Beagle dogs. For investigating possible hPepT1 substrate characteristics, we generated and characterised a CHO-K1 cell line overexpressing SLC15A1 by transfection and selection via magnetic beads. Possible inhibition of the uptake of the prototypical substrate Gly-Sar by octreotide and pasireotide was screened, followed by quantifying the uptake of the cyclic peptides in cells overexpressing SLC15A1 compared with the parental cell line. Although inhibition of Gly-Sar uptake was observed, uptake of octreotide and pasireotide was not increased in SLC15A1 overexpressing cells, indicating a lack of transport by hPepT1. Our data clearly indicate that octreotide and pasireotide are nonsubstrate inhibitors of hPepT1 and that their oral bioavailability cannot be explained by absorption via hPepT1. 
650 4 |a CHO-K1 
650 4 |a glycyl-proline 
650 4 |a glycyl-sarcosine 
650 4 |a LC-MS/MS 
650 4 |a octreotide 
650 4 |a pasireotide 
650 4 |a PepT1 
650 4 |a substrate 
700 1 |a Linde, Teresa von  |e VerfasserIn  |0 (DE-588)1240861192  |0 (DE-627)1769943935  |4 aut 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
700 1 |a Haefeli, Walter E.  |d 1958-  |e VerfasserIn  |0 (DE-588)124572359  |0 (DE-627)656806141  |0 (DE-576)340514221  |4 aut 
700 1 |a Sauter, Max  |e VerfasserIn  |0 (DE-588)1103516507  |0 (DE-627)86126813X  |0 (DE-576)470642033  |4 aut 
700 1 |a Weiß, Johanna  |e VerfasserIn  |0 (DE-588)1050230906  |0 (DE-627)783666322  |0 (DE-576)404441114  |4 aut 
773 0 8 |i Enthalten in  |t Pharmaceutics  |d Basel : MDPI, 2009  |g 14(2022), 8, Artikel-ID 1610, Seite 1-11  |h Online-Ressource  |w (DE-627)614096529  |w (DE-600)2527217-2  |w (DE-576)313958653  |x 1999-4923  |7 nnas  |a Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides 
773 1 8 |g volume:14  |g year:2022  |g number:8  |g elocationid:1610  |g pages:1-11  |g extent:11  |a Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides 
856 4 0 |u https://doi.org/10.3390/pharmaceutics14081610  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/1999-4923/14/8/1610  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220913 
993 |a Article 
994 |a 2022 
998 |g 1050230906  |a Weiß, Johanna  |m 1050230906:Weiß, Johanna  |d 910000  |d 910100  |d 50000  |e 910000PW1050230906  |e 910100PW1050230906  |e 50000PW1050230906  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 6  |y j 
998 |g 1103516507  |a Sauter, Max  |m 1103516507:Sauter, Max  |d 910000  |d 910100  |e 910000PS1103516507  |e 910100PS1103516507  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 124572359  |a Haefeli, Walter E.  |m 124572359:Haefeli, Walter E.  |d 910000  |d 910100  |e 910000PH124572359  |e 910100PH124572359  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1152395823  |a Bajraktari-Sylejmani, Gzona  |m 1152395823:Bajraktari-Sylejmani, Gzona  |d 910000  |d 910100  |e 910000PB1152395823  |e 910100PB1152395823  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1816491004  |e 4187280545 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Gzona","role":"aut","roleDisplay":"VerfasserIn","display":"Bajraktari-Sylejmani, Gzona","family":"Bajraktari-Sylejmani"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Teresa von","display":"Linde, Teresa von","family":"Linde"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Jürgen","display":"Burhenne, Jürgen","family":"Burhenne"},{"family":"Haefeli","roleDisplay":"VerfasserIn","role":"aut","given":"Walter E.","display":"Haefeli, Walter E."},{"family":"Sauter","given":"Max","roleDisplay":"VerfasserIn","role":"aut","display":"Sauter, Max"},{"display":"Weiß, Johanna","given":"Johanna","roleDisplay":"VerfasserIn","role":"aut","family":"Weiß"}],"language":["eng"],"name":{"displayForm":["Gzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, Walter Emil Haefeli, Max Sauter, Johanna Weiss"]},"id":{"eki":["1816491004"],"doi":["10.3390/pharmaceutics14081610"]},"physDesc":[{"extent":"11 S."}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"1 August 2022"}],"relHost":[{"title":[{"title":"Pharmaceutics","title_sort":"Pharmaceutics"}],"language":["eng"],"disp":"Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptidesPharmaceutics","origin":[{"dateIssuedDisp":"2009-","publisher":"MDPI","publisherPlace":"Basel","dateIssuedKey":"2009"}],"name":{"displayForm":["Molecular Diversity Preservation International"]},"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1999-4923"],"zdb":["2527217-2"],"eki":["614096529"]},"part":{"text":"14(2022), 8, Artikel-ID 1610, Seite 1-11","pages":"1-11","year":"2022","extent":"11","volume":"14","issue":"8"},"recId":"614096529","note":["Gesehen am 28.05.14"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2009 -"]}],"title":[{"title":"Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides","title_sort":"Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 13.09.2022"],"recId":"1816491004"} 
SRT |a BAJRAKTARIEVALUATION1202